journal
MENU ▼
Read by QxMD icon Read
search

Biology of Blood and Marrow Transplantation

journal
https://www.readbyqxmd.com/read/28219836/donor-lymphocyte-infusion-for-relapsed-hematological-malignancies-after-unrelated-allogeneic-bone-marrow-transplantation-facilitated-by-the-japan-marrow-donor-program
#1
Toshihiro Miyamoto, Takahiro Fukuda, Marie Nakashima, Tomoko Henzan, Shinsuke Kusakabe, Naoki Kobayashi, Junichi Sugita, Takeshi Mori, Mineo Kurokawa, Shin-Ichiro Mori
To evaluate the safety and efficacy of donor lymphocyte infusion (DLI), we retrospectively analyzed 414 recipients who received unrelated DLI (UDLI) for the treatment of relapsed hematological malignancy after unrelated bone marrow transplantation (BMT). UDLI was administered for acute myelogenous leukemia (n=184), myelodysplastic syndrome (n=69), acute lymphocytic leukemia (n=57), chronic myelogenous leukemia (CML, n=36), lymphoid neoplasms (n=38), adult T-cell leukemia/lymphoma (n=18), and multiple myeloma (n=12)...
February 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28219835/marked-in-vivo-donor-treg-expansion-via-il-2-and-tl1a-ig-stimulation-ameliorates-gvhd-but-preserves-gvl-in-recipients-post-hsct
#2
Dietlinde Wolf, Henry Barreras, Cameron S Bader, Sabrina Copsel, Casey O Lightbourn, Brent J Pfeiffer, Norman H Altman, Eckhard R Podack, Krishna V Komanduri, Robert B Levy
Regulatory T cells (Tregs) are critical for self-tolerance. While adoptive transfer of expanded Tregs limits graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT), ex vivo generation of large numbers of functional Tregs remains difficult. Here, we demonstrate that in vivo targeting of the TNF superfamily receptor TNFRSF25 using the TL1A-Ig fusion protein, along with IL-2, resulted in transient but massive Treg expansion in donor mice, which peaked within days and was nontoxic. Tregs increased in multiple compartments, including blood, lymph nodes, spleen and colon (a GVHD target tissue)...
February 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28219834/incidence-and-outcomes-of-central-nervous-system-hemophagocytic-lymphohistiocytosis-relapse-after-reduced-intensity-conditioning-hematopoietic-stem-cell-transplant
#3
Dana T Lounder, Pooja Khandelwal, Sharat Chandra, Michael B Jordan, Ashish R Kumar, Michael Grimley, Stella M Davies, Jack J Bleesing, Rebecca A Marsh
Hemophagocytic Lymphohistiocytosis (HLH) is an immune regulatory disorder that commonly presents with CNS involvement. The only cure for genetic HLH is hematopoietic stem cell transplantation (HSCT), typically treated with reduced intensity conditioning (RIC) regimens. We sought to estimate the incidence of CNS relapse after RIC HSCT, determine risk factors, and evaluate outcomes. We performed a retrospective chart review of 94 consecutive children and young adults with primary HLH who received RIC HSCT. CNS relapse within 1 year after transplant was diagnosed by review of clinical symptoms, cerebral spinal fluid (CSF), and radiologic findings...
February 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28214595/the-impact-of-delayed-infusion-time-in-umbilical-cord-blood-transplantation
#4
R Mitchell, J E Wagner, C Brunstein, Q Cao, D H McKenna, M R Verneris
In umbilical cord blood (UCB) transplantation, UCB units are typically thawed, washed and infused into the patient as rapidly as possible. In some instances, there is a delay in the time from the unit thaw/wash procedure to infusion into the patient. Therefore, we examined the effect of thaw duration time on engraftment outcomes in 567 patients undergoing UCB transplantation. With a range of 32 to 523 minutes, a prolonged thaw duration had no obvious effect on the incidence of neutrophil engraftment or time to recovery...
February 15, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28212937/the-impact-of-alemtuzumab-scheduling-on-graft-versus-host-disease-following-unrelated-donor-fludarabine-and-melphalan-allografts
#5
Kile Green, Kim Pearce, Rob S Sellar, Laura Jardine, Phillip Lr Nicolson, Sandeep Nagra, Venetia Bigley, Graham Jackson, Anne M Dickinson, Kirsty Thomson, Stephen Mackinnon, Charles Craddock, Karl S Peggs, Matthew Collin
Alemtuzumab conditioning is highly effective at reducing the incidence of acute and chronic graft versus host disease (GVHD) in reduced intensity fludarabine and melphalan transplantation with ciclosporin monotherapy. Less frequent and lower dose scheduling may be used with sibling donors but an optimal regimen for matched unrelated donors has not been defined. In this retrospective observational study of 313 patients, the incidence and severity of GVHD was compared in patients receiving three different dose schedules: the standard 100mg regimen (20mg on day -7 to -3), 60mg (30mg day -4 and -2) or 50mg (10mg on day -7 to -3)...
February 14, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28192253/hematopoietic-stem-cell-transplantation-using-preimplantation-genetic-diagnosis-and-hla-typing-for-hla-matched-sibling-donor-a-turkish-multicenter-study
#6
Emin Kurekci, Alphan Küpesiz, Sema Anak, Gülyüz Öztürk, Orhan Gürsel, Serap Aksoylar, Talia Ileri, Barış Kuşkonmaz, Ibrahim Eker, Mualla Cetin, Gülsün Tezcan Karasu, Zühre Kaya, Tunç Fışgın, Mehmet Ertem, Savaş Kansoy, Mehmet Akif Yeşilipek
Preimplantation genetic diagnosis involves the diagnosis of a genetic disorder in embryos obtained through in vitro fertilization, selection of healthy embryos, and transferring them to the mother's uterus. Preimplantation genetic diagnosis has been used not only to avoid the risk of having an affected child, but also by using HLA matching together, it offers preselection of potential HLA-genoidentical healthy donor progeny for an affected sibling, who requires bone marrow transplantation. Here, we share the hematopoietic stem cell transplantation results of 52 patients with different benign and malign hematological or metabolic diseases or immunodeficiencies, whose donors were their siblings borned with this technique in Turkey since 2008...
February 10, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28192252/the-bottom-line-total-marrow-and-lymphoid-irradiation-to-rescue-refractory-leukemia
#7
Pritesh R Patel, Damiano Rondelli
No abstract text is available yet for this article.
February 10, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28192251/antibiotic-induced-depletion-of-anti-inflammatory-clostridia-is-associated-with-the-development-of-gvhd-in-pediatric-stem-cell-transplant-patients
#8
Tiffany R Simms-Waldrip, Gauri Sunkersett, Laura A Coughlin, Milan R Savani, Carlos Arana, Jiwoong Kim, Minsoo Kim, Xiaowei Zhan, David E Greenberg, Yang Xie, Stella M Davies, Andrew Y Koh
Adult stem cell transplantation (SCT) patients with graft-versus-host-disease (GVHD) exhibit significant disruptions in gut microbial communities. These changes are associated with higher overall mortality and appear to be driven by specific antibiotic therapies. It is unclear whether pediatric SCT patients who develop GVHD exhibit similar antibiotic-induced gut microbiota community changes. Here, we show that pediatric SCT patients (from Children's Medical Center Dallas, n=8, and Cincinnati Children's Hospital, n=7) who develop GVHD show a significant decline, up to 10-log fold, in gut anti-inflammatory Clostridia (AIC), compared to those without GVHD...
February 9, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28189904/prognostic-value-of-the-hematopoietic-cell-transplantation-comorbidity-index-for-patients-undergoing-reduced-intensity-conditioning-cord-blood-transplantation
#9
Rachel B Salit, David C Oliver, Colleen Delaney, Mohamed L Sorror, Filippo Milano
The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) has been validated as a tool for evaluating the risk of treatment-related mortality (TRM) in HLA-matched sibling and matched unrelated donor bone marrow and peripheral blood stem cell transplantation patients. However, the role of the HCT-CI after cord blood transplantation (CBT) has not been fully investigated. In this analysis, we sought to evaluate the predictive value of the HCT-CI in patients undergoing reduced-intensity conditioning (RIC) CBT...
February 9, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28189903/cytogenetic-evolution-in-myeloid-neoplasms-at-relapse-after-allogeneic-hematopoietic-cell-transplantation-association-with-previous-chemotherapy-and-effect-on-survival
#10
Natalie Ertz-Archambault, Heidi Kosiorek, James L Slack, Melissa L Lonzo, Patricia T Greipp, Nandita Khera, Katalin Kelemen
Cytogenetic evolution (CGE) in patients with myeloid neoplasms who relapsed after an allogeneic hematopoietic cell transplantation (allo-HCT) has been evaluated by only few studies. The effect of the CGE on survival of relapsed allo-HCT recipients is not clear. The effect of previously received chemotherapy to induce CGE in this patient population has not been studied. The aim of our study is to a) characterize the patterns of cytogenetic change in patients with myeloid neoplasms who relapsed after an allo-HCT; b) evaluate the effect of CGE on survival; c) explore the association of CGE with previous chemotherapy (including the lines of salvage therapy, type of induction and conditioning therapy)...
February 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28189902/decitabine-prior-to-low-dose-cytarabine-based-chemotherapy-combined-with-hla-mismatched-stem-cell-micro-transplantation-improved-outcomes-in-elderly-patients-with-newly-diagnosed-acute-myeloid-leukaemia
#11
Yu Zhu, Huihui Zhao, Xiaoyan Zhang, Yujie Wu, Yue Xie, Yanru Li, Yun Lian, Jiayu Huang, Jianyong Li, Yaoyu Chen, Sixuan Qian
The optimal treatment for elderly patients with acute myeloid leukaemia (AML) remains a great challenge. It is urgent and necessary to set up a more feasible, acceptable, accessible and safe treatment strategy for elderly patients. We conducted a prospective study of 23 elderly patients (median age 68 years; range from 60 to 87 years old) with newly diagnosed AML to evaluate the efficacy and toxicity of decitabine plus G-CSF priming, low-dose aclarubicin and cytarabine (DCAG) chemotherapy combined with human leukocyte antigen (HLA) mismatched stem cell micro-transplantation (SC-MST) without graft-versus-host disease (GVHD) prophylaxis...
February 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28183535/erratum-to-risk-factors-and-outcomes-of-infections-by-multidrug-resistant-gram-negative-bacteria-in-patients-undergoing-hematopoietic-stem-cell-transplantation-biol-blood-marrow-transplant-2017-23-333-339
#12
Francesca Patriarca, Chiara Cigana, Massimo Dozzo, Davide Lazzarotto, Antonella Geromin, Miriam Isola, Marta Lisa Battista, Marta Medeot, Michela Cerno, Alessandra Sperotto, Anna Candoni, Massimo Crapis, Assunta Sartor, Claudio Scarparo, Matteo Bassetti, Renato Fanin
No abstract text is available yet for this article.
February 6, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28167153/the-fifth-egf-like-region-of-thrombomodulin-alleviates-murine-graft-versus-host-disease-in-a-g-protein-coupled-receptor-15-dependent-manner
#13
Bin Pan, Xiangmin Wang, Shinsuke Kojima, Chie Nishioka, Akihito Yokoyama, Goichi Honda, Kailin Xu, Takayuki Ikezoe
Thrombomodulin (TM) exerts anti-inflammatory functions. We previously found that recombinant human soluble thrombomodulin (rTM) alleviated murine graft-versus-host disease (GVHD). Nevertheless, it is unclear how TM mediates its anti-inflammatory functions in GVHD. Here, we identified G-protein coupled receptor 15 (GPR15) expressed on T cells as a receptor/sensor of TM. The fifth region of epidermal growth factor(EGF)-like domain of TM (TME5) bound GPR15 in vitro. TME5 prolonged survival of mice undergoing aGVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT)...
February 3, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28167152/the-prognostic-limitations-of-donor-t-cell-chimerism-after-myeloablative-allogeneic-stem-cell-transplantation-for-acute-myeloid-leukemia-and-myelodysplastic-syndromes
#14
Eric Wong, Kate Mason, Jenny Collins, Barbara Hockridge, Janis Boyd, Alexandra Gorelik, Jeffrey Szer, David S Ritchie
Donor T-cell chimerism is associated with relapse outcomes after allogeneic stem cell transplantation (alloSCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). However, measures of statistical association do not adequately assess the performance of a prognostic biomarker, which is best characterized by its sensitivity and specificity for the chosen outcome. We analyzed donor T-cell chimerism results at day 100 (D100chim) after myeloablative alloSCT for AML or MDS in 103 patients, and determined its sensitivity and specificity for relapse free survival at 6 months (RFS6) and 12 months (RFS12) post-alloSCT...
February 3, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28161608/allogeneic-hematopoietic-cell-transplantation-for-aggressive-nk-cell-leukemia-a-cibmtr-analysis
#15
Mehdi Hamadani, Abraham S Kanate, Alyssa DiGilio, Kwang Woo Ahn, Sonali M Smith, Jong Wook Lee, Ernesto Ayala, Nelson Chao, Parameswaran Hari, Javier Bolaños-Meade, Ronald Gress, Niels Smedegaard Anderson, Yi-Bin Chen, Umar Farooq, Gary Schiller, Jean Yared, Anna Sureda, Timothy S Fenske, Horatiu Olteanu
Aggressive NK-cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis with a median survival of only 2-months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in patients with ANKL. Twenty-one patients with a centrally confirmed diagnosis of ANKL were included. Median patient age was 42-years and 15 patients (71%) were Caucasian. Fourteen patients (67%) were in complete remission (CR) at the time of alloHCT, while 5 patients had active disease...
February 1, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28161607/targeting-the-canonical-nf-%C3%AE%C2%BAb-pathway-with-a-high-potency-ikk2-inhibitor-improves-outcomes-in-a-mouse-model-of-idiopathic-pneumonia-syndrome
#16
Kenneth A Fowler, Corey M Jania, Stephen L Tilley, Angela Panoskaltsis-Mortari, Albert S Baldwin, Jonathan S Serody, James M Coghill
Idiopathic pneumonia syndrome (IPS) is a non-infectious, inflammatory disorder of the lungs that occurs most often after fully myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). IPS can be severe and is associated with high one year mortality rates despite existing therapies. The canonical NF-κB signaling pathway has previously been linked to several inflammatory disorders of the lung including asthma and lung allograft rejection. It has never been specifically targeted as a novel IPS treatment approach, however...
February 1, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28132870/bmt-roadmap-a-user-centered-design-health-information-technology-tool-to-promote-patient-centered-care-in-pediatric-hct
#17
Lyndsey Runaas, David Hanauer, Molly Maher, Evan Bischoff, Alex Fauer, Tiffany Hoang, Anna Munaco, Roshun Sankaran, Rahael Gupta, Sajjad Seyedsalehi, Amy Cohn, Larry An, Muneesh Tewari, Sung Won Choi
Health information technology (HIT) has great potential for increasing patient engagement. Pediatric HCT is a setting ripe for using HIT but in which little research exists. "BMT Roadmap" is a web-based application that integrates patient-specific information and includes several domains: laboratory results, medications, clinical trial details, photos of the healthcare team, trajectory of transplant process, and discharge checklist. BMT Roadmap was provided to 10 caregivers of patients undergoing first-time HCT...
January 26, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28132869/bone-marrow-derived-mesenchymal-stromal-cells-from-sickle-cell-disease-patients-display-intact-functionality
#18
Elizabeth O Stenger, Raghavan Chinnadurai, Shala Yuan, Marco Garcia, Dalia Arafat, Greg Gibson, Lakshmanan Krishnamurti, Jacques Galipeau
Hematopoietic cell transplantation (HCT) is the only cure for sickle cell disease (SCD), but engraftment remains challenging in patients lacking matched donors. Infusion of mesenchymal stromal cells (MSCs) at time of HCT may promote hematopoiesis and ameliorate graft-versus-host disease. Experimental murine models suggest MSC major histocompatibility complex compatibility with recipient impacts their in vivo function, suggesting autologous MSCs could be superior to third-party MSCs for promoting HCT engraftment...
January 26, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28115278/the-role-of-thromboelastography-teg-in-pediatric-patients-with-sinusoidal-obstructive-syndrome-receiving-defibrotide
#19
Joanna L Gendreau, Christine Knoll, Roberta H Adams, Leon L Su
Sinusoidal obstructive syndrome (SOS) is a potentially fatal form of hepatic injury following hematopoietic stem cell transplant (HSCT). Patients can develop liver dysfunction, portal hypertension, ascites, coagulopathies, and multi-system organ failure. The mortality rate of severe SOS has been reported as high as 98% by Day 100 post-transplant. Defibrotide, which is now approved for the treatment of SOS, has significantly decreased mortality. Defibrotide is a polynucleotide with pro-fibrinolytic, anti-ischemic, and anti-inflammatory activity...
January 20, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28115277/impact-of-post-transplant-response-and-minimal-residual-disease-on-survival-in-myeloma-with-high-risk-cytogenetics
#20
Rajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, Dragan Jevremovic, Francis K Buadi, David Dingli, Angela Dispenzieri, Suzanne R Hayman, William J Hogan, Prashant Kapoor, Martha Q Lacy, Nelson Leung, Morie A Gertz
The impact of depth of response and minimal residual disease (MRD) status on survival is not well defined in multiple myeloma (MM) with high-risk (HR) cytogenetics, due to low representation of such patients in clinical trials. We have evaluated the impact of post-transplant stringent complete response (sCR) and MRD-status on progression-free survival (PFS) and overall survival (OS) in 185 consecutive MM patients with HR FISH cytogenetics undergoing upfront autologous stem cell transplantation (ASCT) between 2007 and 2015 in our institution...
January 20, 2017: Biology of Blood and Marrow Transplantation
journal
journal
20050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"